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Study Objectives: Scleroderma is associated with abnormal skin thickening, interstitial lung disease, pulmonary hypertension, and abnormalities of the upper
airway. These changes can cause cardiopulmonary complications, potentially including sleep-disordered breathing. The objective of this study is to examine the risk
of sleep-disordered breathing in patients with scleroderma.
Methods:We retrospectively identiﬁed patients with documented scleroderma. We abstracted data from their electronic health records, including ﬁndings from
antibody tests, serial pulmonary function tests, transthoracic echocardiography, high-resolution computed tomography, and overnight forehead oximetry.
Results:We identiﬁed 171 patients with scleroderma. Mean age at the time of initial consult was 56.5 years (range, 18–96 years), and 150 (86.7%) were women.
Scleroderma was categorized as limited disease for 108 (62.4%), diffuse disease for 59 (34.1%), and mixed connective tissue disease for 6 (3.5%). Fifty-four
patients (31.2%) had abnormal overnight forehead oximetry results, deﬁned as an oxygen desaturation index greater than 5 or a baseline mean arterial oxygen
saturation level less than 90%.
Conclusions: Cardiopulmonary complications are common in patients with scleroderma, one of which may be sleep-disordered breathing. In our cohort,
approximately one-third of individuals with scleroderma had evidence of sleep-disordered breathing. Moreover, the rate of sleep-disordered breathing in our
population of scleroderma patients was twice the rate of pulmonary hypertension and was approximately the same as the rate of interstitial lung disease. Future
prospective studies are needed to further assess the role of sleep-disordered breathing in scleroderma clinical outcomes.
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BRIEF SUMMARY
Current Knowledge/Study Rationale: Cardiopulmonary complications are a common manifestation of systemic sclerosis. To date, the prevalence for
sleep disordered breathing may be underappreciated.
Study Impact: To our knowledge, this is the ﬁrst study of this size to look at overnight oximetry data and extrapolate the potential prevalence of sleep-
disordered breathing in scleroderma.
INTRODUCTION
Scleroderma (also termed systemic sclerosis [SSc]) is a condition
associated with abnormal skin thickening, interstitial lung dis-
ease (ILD), pulmonary hypertension (PH), esophageal motility
disorders, and other complications.1 SSc is a rare disorder, with
an incidence rate of 2.3 to 22.8 cases per million persons per
year.1 Because of the clinical rarity of SSc, study of the disease
course and its effect on sleep has been minimal.1
Scleroderma is broadly categorized as limited or diffuse, as
determined by the modiﬁed Rodnan skin score,1 which con-
siders the distribution and severity of skin thickening. Dif-
fuse as compared to limited SSc is more likely to be associated
with internal organ involvement.1 Moreover, scleroderma,
especially the diffuse type, is known to cause oropharyngeal
dysfunction,2,3 which may be important in maintaining
upper airway patency. The risk of ILD and PH for patients with
scleroderma varies with autoantibody subtype.4 Accordingly,
the broad array of cardiopulmonary phenotypes in SSc led us to
hypothesize that scleroderma might be associated with sleep-
disordered breathing (SDB).
Onemethod of screening for SDB is pulse oximetry. This is a
valid and cost-effective tool for screening for SDB.5 Although
polysomnography (PSG) is the gold standard in screening
for SDB, overnight oximetry is a reasonable screening test.6
Evidence of SDB that can be obtained from pulse oximetry
include: low pulse oximetry (SpO2) values, elevated oxygen
desaturation index (ODI), or the presence of sawtoothing all can
suggest evidence of SDB. There is no universally agreed upon
ODI cutoff for evidence of SDB, but a cutoff of ≥ 4 events/h is
generally used.5,7,8 Notably, the accuracy of pulse oximetry can
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be affected by peripheral vasoconstriction9 as well as the digital
remodeling seen in SSc. For this reason, we chose to use
forehead oximetry as a screening tool for SDB in individuals
with SSc as part of a comprehensive scleroderma assessment
at our tertiary referral center. Forehead, ﬁnger, and ears are all re-
liable sites for oximetry, because of the increasedvascular density in
these areas (relative to the trunk or other sites).9 Moreover, in
routine cardiopulmonary assessments of individuals with sclero-
derma, forehead oximetry is likely a superior modality for SpO2
assessment.10 In a limited number of agreeable participants, we
were also able to obtain dedicated PSG tests. In so doing, we
sought to evaluate the prevalence of SDB in SSc.
METHODS
This study was approved by the Mayo Clinic Institutional
Review Board.
Data Collection
We retrospectively reviewed records of patients seen at Mayo
Clinic (Phoenix, Arizona), a tertiary referral center, from
January 1, 2005, through December 31, 2015, for scleroderma
evaluation. All patients were seen by one rheumatologist
(WLG) and all had a uniform assessment that included clinical
evaluation, laboratory tests (including antibody tests), echocar-
diography, pulmonary function tests, high-resolution computed
tomography (CT), and overnight oximetry with a forehead
probe. Forehead oximetry was chosen instead of ﬁnger pulse
oximetry because of the high prevalence of Raynaud phe-
nomenon among patients with scleroderma. Forehead oximetry
is a suitable alternative when peripheral oximetry is not an
option.11 Study data were collected and managed using RED-
Cap (Research Electronic Data Capture) tools hosted at Mayo
Clinic.12 REDCap is a secure, Web-based application designed
to support data capture for research studies, providing (1) an
intuitive interface for validated data entry; (2) audit trails for
tracking data manipulation and export procedures; (3) automated
export procedures for seamless data downloads to common
statistical packages; and (4) procedures for importing data from
external sources.
From this database, we reviewed all overnight oximetry
studies for evidence of SDB. Overnight oximetry was per-
formed by using a Nonin PalmSat 2500 oximeter (Nonin
Medical, Tilburg, the Netherlands) and analyzed with Profox
oximetry software (Profox, Coral Springs, Florida). The ODI
was calculated by dividing the total number of desaturation
events of 4% or greater by the total hours of recording time. An
ODI value greater than 5 events/h was considered abnormal.
A mean oxygen saturation as measured by SpO2 level below
90% for the entire recording was also considered abnormal.
Time below 90% was unfortunately not routinely denoted on
oximetry reports unless it was abnormal by the reading sleep
physician. Each oximetry tracing was manually inspected by
our evidence of SDB, including low SpO2, elevated ODI, or the
presence of sawtoothing.
We also obtained demographic data for all patients, in-
cluding sex, age at consult, and body mass index. The
presence of ILD was determined by reviewing pulmonary
function tests and reports of high-resolution thoracic CT.
A restrictive pattern on pulmonary function studies was de-
termined by a total lung capacity of less than 80% of the
predicted normal value and a diffusing capacity of lung
for carbon monoxide of less than 80% of the predicted nor-
mal. All thoracic CT images were interpreted by a thoracic
radiologist, who commented on degree of ﬁbrosis, honey-
combing, pulmonary artery size, and whether the esophagus
was considered patulous.
PH was deﬁned by a mean pulmonary artery pressure ex-
ceeding 25 mm Hg in those who underwent right-sided heart
catheterization. Elevated right ventricular systolic pressure on
echocardiographywas used as a screening parameter for referral
for possible right-heart catheterization.
Statistical Analyses
Logistic regression analysis was used to test the predictive ca-
pacity of covariates on abnormal oximetry ﬁndings, deﬁned as
whether a patient had an ODI greater than 5 or a mean oxygen
saturation less than 90%.Values of P < .05 were considered
signiﬁcant. Descriptive analyses regarding dedicated sleep
studies were extracted directly from REDCap.
RESULTS
We identiﬁed 171 patients with scleroderma. Baseline patient
demographic data are detailed in Table 1. None were on sup-
plemental oxygen before or during the oximetry study. In the
cohort, 55 patients (32.1%) had abnormal overnight forehead
oximetryﬁndings. Fifty-two patients had an elevatedODI (≥ 5).
Of those patients with abnormal oximetry readings, the median
ODI was 8.2/h (interquartile range, 6.0–11.8) and the mean
SpO2 was 92.9%.
Of these 53 with an elevated ODI, 47 had a normal mean
SpO2, whereas 6 had a low mean SpO2. Two patients had low
mean SpO2 without an elevated ODI. Four of the patients with
elevated ODI also had evidence of “sawtoothing” on the oxi-
metry tracing. Sawtoothingwas not demonstrated in the absence
of an elevated ODI.
Of the subgroup with low baseline SpO2 2 had PH without
ILD, 1 had both ILD and PH, and 5 had neither ILD nor PH.
Table 1—Patient characteristics (n = 171).
Characteristic Value
Age at consult, years, mean (SD) 56.5 (14.6)
Female sex, n (%) 150 (86.7)
Scleroderma type, n (%)
Diffuse 59 (34.1)
Limited 108 (62.4)
Mixed connective tissue disease 6 (3.5)
SD = standard deviation.
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(Table 2). There were no speciﬁc autoantibodies that predicted
abnormal oximetry.
Regression analysis showed that the only predictive var-
iables for abnormal oximetry were age (P < .001) and en-
larged pulmonary artery diameter (P = .03); the presence of
ILD, PH (as measured by right heart catheterization), smoking
history, or scleroderma subtype (diffuse, limited, mixed con-
nective tissue disease) were not predictive factors (Table 3).
Of those with abnormal oximetry, 17 patients agreed to
undergo full polysomnography. Of these, 13 (76.5%) had
limited scleroderma, 8 (47.1%) had ILD, and 4 (23.5%) had
PH. None were smokers or had chronic obstructive pulmonary
disease. The mean apnea-hypopnea index was 15.6 events/h,
the mean time below 90% oxygen saturation was 16.2%, the
mean respiratory disturbance index was 22.4 events/h. Six of
the 17 patients who underwent PSG had concerns about ex-
cessive sleepiness; however, they had normal PSG ﬁndings
and normal overnight oximetry readings. Seven patients
had elevated apnea-hypopnea indices that corresponded to
abnormalODIs on oximetry, and four had low baseline oxygen
saturation. The sleep study data for these 17 patients are shown
in Table 4.
DISCUSSION
Our study represents a unique opportunity to examine sleep
disturbance associated with scleroderma. Although the study
was limited by its retrospective design, we describe a uniquely
large cohort of patients with a clinically rare disease that un-
derwent a uniform cardiopulmonary assessment.
As noted, a multitude of cardiopulmonary outcomes, such
as PH and ILD, are attributable to scleroderma. PH and ILD
are often associated with SDB. In particular, patients with
ILD have abnormal sleep architecture, a markedly increased
risk of sleep apnea, and nocturnal oxygen desaturation that
may manifest as an elevated ODI.13 Further, individuals with
World Health Organization group 1 PH have increased risk of
Table 2—Predictors of abnormal oximetry ﬁndings.
Characteristic Patients With Abnormal Oximetry Findings(n = 55)
Patients With Normal Oximetry Findings
(n = 116) P
Age, years, mean (SD) 62.0 (13.1) 53.6 (14.6) < .001 *
Body mass index, kg/m2, mean (SD) 25.3 (5.2) 24.5 (5.6) .41 *
Interstitial lung disease, n (%) 17 (30.9) 46 (39.7) .27
Limited disease, n (%) 29 (52.7) 79 (68.1) .13
Diffuse disease, n (%) 23 (41.8) 34 (29.3) .13
Pulmonary hypertension, n (%) 7 (12.7) 18 (15.7) .61
Baseline FEV1, mean (SD) 85.3 (15.8) 86.5 (18.0) .66 *
Baseline FVC, mean (SD) 85.0 (16.4) 86.3 (17.9) .66 *
Baseline DLCO, mean (SD) 75.8 (20.8) 76.0 (24.5) .95 †
Baseline TLC, mean (SD) 89.1 (15.9) 91.2 (16.2) .43 *
Oxygen desaturation index data were missing for two patients. * Continuous variables were assessed with unpaired t tests. † Categorical variables were
assessedwith χ2 tests. Values ofP <.05were considered signiﬁcant. DLCO= diffusing capacity of lung for carbonmonoxide, FEV1 = forced expiratory volume in
the ﬁrst second of expiration, FVC = forced vital capacity, SD = standard deviation, TLC = total lung capacity.
Table 3—Logistic regression for predictive factors of abnormal overnight oximetry ﬁndings.
Factor
Odds Ratio Estimates
Point Estimate 95% Wald Conﬁdence Limits P
Age at consult 0.957 0.927–0.988 < .01
Interstitial lung disease, reference = no 1.021 0.334–3.123 .97
Pulmonary hypertension, reference = no 1.572 0.492–5.030 .45
Scleroderma type, reference = limited
Diffuse 0.308 0.121–0.785 .39
MCTD 0.357 0.024–5.413 .75
Pack-years 0.998 0.971–1.025 .88
Patulous esophagus reference = no 0.986 0.427–2.278 .97
PA > 3 cm diameter 0.359 0.153–0.844 .02
Fibrosis (each 25% increase in top, middle, or bottom) 1.153 0.970–1.370 .11
Logistic regression output modeled “pulse oximetry” as “normal.” MCTD = mixed connective tissue disease, PA = pulmonary artery.
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SDB.14 Minic et al.15 showed an increased risk of central and
obstructive sleep apnea in individuals with World Health Orga-
nization group 1 PH. Risk factors for SDB within this population
were older age and increased Epworth Sleepiness Scale score.
Webelieve that, in addition to PHand ILD, scleroderma itself
was an independent risk factor for SDB.4,14–16 Scleroderma,
especially the diffuse type, is known to cause oropharyngeal
dysfunction, which may predispose patients toward SDB.2,3
Scleroderma is characterized by immune dysregulation−associated
vascular changes and ﬁbrosis1; these changes affect systemic
and pulmonary vascular beds, esophageal mucosal surfaces,
and the pharynx.1,17 Scleroderma can cause cricoarytenoid
ankyloses, vocal cord nodules, and vocal cord dysfunction,
all of which could potentially contribute to SDB.18
Despite the potential for cardiopulmonary pathology in
SSc, few studies have evaluated the risk of SDB in patients
with scleroderma.19 Small, survey-based studies about quality
of life and sleep were conducted by Frech et al19 Prado and
colleagues20 assessed the sleep studies of a small group of
patients with scleroderma (n = 27) and noted no increased risk
for SDB, but they did observe that patientswith SSc had reduced
sleep efﬁciency, less rapid-eye movement sleep, and increased
arousal index and slow-wave sleep.
In our study, the predictive variables for abnormal overnight
oximetry included patient age, which is a risk factor for SDB,
irrespective of the presence of underlying lung disease.21
However, the presence of ILD and PH were not predictive of
abnormal overnight oximetry ﬁndings, even though they are
well-deﬁned risk factors for SDB. We speculate that those
patients still had risk of SDB because of oropharyngeal and
laryngealﬁbrosis, though this is not explicitly noted in reviewof
their clinical visits.
The greatest limitation of our study is that it is retrospective
and based on chart review. We did not have a sufﬁcient number
of dedicated sleep studies because many of these patients came
from a broad geographic area and were often not able to stay for
formal sleep studies following abnormal oximetry. Forehead
oximetry as a modality for assessing presence of SDBmay also
be problematic, as there is a chance of spuriously low SpO2with
forehead oximetry, especially if the probe is insufﬁciently se-
cured. However, we were able to manually review each of our
tracings for quality assurance.
Despite these limitations, our study is the largest assessment
to date of the prevalence of SDB in SSc. Prospective studies
evaluating SDB in scleroderma may better determine the effect
of this condition on prognosis, and whether therapies such as
positive airway pressure are effective.
ABBREVIATIONS
CT, computed tomography
ILD, interstitial lung disease
ODI, oxygen desaturation index
PH, pulmonary hypertension
PSG, polysomnography
REDCap, Research Electronic Data Capture
SDB, sleep-disordered breathing
SpO2, oxygen saturation
SSc, systemic sclerosis
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